3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Polycythemia Vera
4
Leukemia, Myeloid, Acute
4
Treatment-Refractory Solid Tumors
2
Meningioma
2
Squamous Cell Carcinoma of Head and Neck
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myelodysplastic Syndromes
1
Lymphoma, Follicular
1
Leukemia, Myelomonocytic, Chronic
1
Head and Neck Neoplasms
1
Bone Marrow Neoplasms
1
Bites and Stings
1
Interventions
pembrolizumab
2
enzalutamide
2
abiraterone
2
Immune Checkpoint Inhibitors
2
Cytochrome P-450 Enzyme System
2
durvalumab
1
dostarlimab
1
cemiplimab
1
blinatumomab
1
atezolizumab
1
Surgical Instruments
1
Hydroxyurea
1
Etoposide
1
Etanercept
1
Carboplatin
1
Androgen Receptor Antagonists
1
AMG 757
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Bites and Stings
×
Hydroxyurea
×
1 year
×
Clear all
NCT06063317
2026-03-06
OASIS
Imugene Limited
Phase 1
Terminated
25 enrolled